Results 181 to 190 of about 6,718,063 (241)

A Cost-Effectiveness Analysis for Treatments of Patients with Early Stage Huntington's Disease in the USA. [PDF]

Pharmacoecon Open
Patil D, Slejko JF, Savitt JM, Mattingly Ii TJ.   +3 more
europepmc   +1 more source

Race and Household Income Are Associated With Disease Outcomes in Pediatric Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Hospitalized in the United States

Arthritis Care &Research, EarlyView.
Objective Race and household income impact outcomes in patients with rheumatic conditions; however, their role in pediatric antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) remains poorly understood. We aimed to evaluate whether race and ethnicity and household income are associated with severe AAV disease and renal outcomes among
Roberto Alejandro Valdovinos, William Daniel Soulsby III, Emily von Scheven   +2 more
wiley   +1 more source

Cost-effectiveness of the special care unit for persons with dementia. [PDF]

J Prev Alzheimers Dis
Handels R, Michalowsky B, Mendes A, Bergh S, Cesana BM, Ciccone A, Cognat E, Fabbo A, Fascendini S, Frisoni GB, Froelich L, Mecocci P, Merlo P, Peters O, Tsolaki M, Defanti CA, RECage consortium collaborators.   +16 more
europepmc   +1 more source

Immunosuppressive Drug Use in Limited Systemic Sclerosis: An International Survey

Arthritis Care &Research, EarlyView.
Objective Current guidelines recommend immunosuppressive treatment for diffuse cutaneous systemic sclerosis but are less clear on their use in limited cutaneous systemic sclerosis (lcSSc) in the absence of internal organ complications. We conducted an international survey to understand current immunosuppressive drug prescribing patterns in lcSSc ...
Sabrina Hoa, Yicheng Mu, Marie Hudson, Janet Pope   +3 more
wiley   +1 more source

Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer.

JAMA Netw Open
Su ZT, Garman TS, Rivera Lopez CA, Talwar R, Chelluri R, Johnson BA, Patel HD, Sood A, Smith AK, Singla N, Hoffman-Censits JH, Patel SH, Daneshmand S, Nielsen ME, Bivalacqua TJ, Boorjian SA, Hahn NM, Townsend JP, Kates MR.   +18 more
europepmc   +1 more source

Cost-Effectiveness of Pitavastatin in Dyslipidemia: A Systematic Review. [PDF]

Healthcare (Basel)
Vo NX, Pham HL, Bui TT, Bui TT.
europepmc   +1 more source

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

Arthritis Care &Research, EarlyView.
Objective We aimed to determine whether the short‐term response to biologics in biologic‐naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis.
Sung Min Cho, Shangyi Gao, Daniel Pereira, Richard J. Cook, Dafna D. Gladman   +4 more
wiley   +1 more source

What Does "Success" Mean in the Cost-Effectiveness of Fetal Fibronectin Testing? [Letter]. [PDF]

Clinicoecon Outcomes Res
Sarıoğlu G.
europepmc   +1 more source

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

Arthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko, Ray Zhang, Sohini Mukherjee, Puneet Bajaj, Bonnie L. Bermas   +4 more
wiley   +1 more source

Cost-effectiveness of QuantiFERON for TB infection screening in household contacts in the Philippines. [PDF]

IJTLD Open
Mortera LL, Padua JO, Alagna R.
europepmc   +1 more source